University of Colorado Denver and Hospital
Welcome,         Profile    Billing    Logout  
 4 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Menard-Katcher, Paul
DEGS, NCT03678545: Dupilumab in Eosinophilic Gastritis

Active, not recruiting
2
41
US
Dupilumab (blinded), Placebo (blinded), Dupilumab (open-label)
Children's Hospital Medical Center, Cincinnati, Regeneron Pharmaceuticals, National Institutes of Health (NIH)
Eosinophilic Gastritis, Eosinophilic Gastroenteritis
03/24
11/24
NCT02008903: Esophageal String Test in Eosinophilic Esophagitis

Active, not recruiting
N/A
440
US
University of Colorado, Denver, University of Illinois at Chicago, Northwestern University, OSF Healthcare System
Eosinophilic Esophagitis
01/25
01/25
SWAT-BE, NCT05530343: Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance

Recruiting
N/A
2298
US
Seattle protocol, WATS3D brushings
University of Colorado, Denver
Barrett Esophagus, Barretts Esophagus With Dysplasia, Esophageal Adenocarcinoma
03/26
03/26
NCT02523118: OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages

Recruiting
N/A
1350
US
Children's Hospital Medical Center, Cincinnati, National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), ORDR, National Center for Advancing Translational Sciences (NCATS)
Eosinophilic Gastrointestinal Disorders (EGIDs), Eosinophilic Esophagitis, Eosinophilic Gastritis, Eosinophilic Gastroenteritis, Eosinophilic Colitis
12/50
01/51
Forman, Lisa
NCT01846663: Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy

Terminated
4
6
US
Placebo, Rifaximin, XIFAXAN® Tablets
Bausch Health Americas, Inc.
Hepatic Encephalopathy
02/16
02/16
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
NCT05569759: A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)

Active, not recruiting
2
24
US
zetomipzomib, KZR-616, placebo, sterile water for injection, zetomipzomib in open-label extension
Kezar Life Sciences, Inc.
Autoimmune Hepatitis
02/25
08/25
NCT06699121: A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC

Not yet recruiting
2
87
US
LB-P8 low-dose, LB-P8 high-dose, Placebo
LISCure Biosciences
Primary Sclerosing Cholangitis (PSC)
03/28
02/29
Cahoon, Jonathon
DEGS, NCT03678545: Dupilumab in Eosinophilic Gastritis

Active, not recruiting
2
41
US
Dupilumab (blinded), Placebo (blinded), Dupilumab (open-label)
Children's Hospital Medical Center, Cincinnati, Regeneron Pharmaceuticals, National Institutes of Health (NIH)
Eosinophilic Gastritis, Eosinophilic Gastroenteritis
03/24
11/24
NCT02008903: Esophageal String Test in Eosinophilic Esophagitis

Active, not recruiting
N/A
440
US
University of Colorado, Denver, University of Illinois at Chicago, Northwestern University, OSF Healthcare System
Eosinophilic Esophagitis
01/25
01/25
Rasti, Aryana
No trials found

Download Options